UNDERWRITING AGREEMENT among GLAXOSMITHKLINE CAPITAL INC. as Issuer GLAXOSMITHKLINE PLC as Guarantor and as Representatives of the Underwriters Dated as of [ ]Underwriting Agreement • March 4th, 2008 • Glaxosmithkline Capital PLC • Pharmaceutical preparations • New York
Contract Type FiledMarch 4th, 2008 Company Industry JurisdictionWe have acted as special United States counsel to GlaxoSmithKline Capital Inc., a Delaware corporation (“GSK Capital Inc.”), and GlaxoSmithKline plc, a public limited company incorporated in England and Wales (the “Guarantor”), in connection with the offering from time to time, together or separately and in one or more series, pursuant to a registration statement on Form F-3 (No. 333-[ ]) of (i) guaranteed debt securities of GSK Capital Inc. (the “Debt Securities”) and (ii) guarantees of the Guarantor in respect of the Debt Securities (the “Guarantees” and, together with the Debt Securities, the “Securities”) to be issued under an indenture dated as of April 6, 2004 (the “Indenture”) among GSK Capital Inc., the Guarantor and Law Debenture Trust Company of New York (as successor to Citibank, N.A., pursuant to an Instrument of Resignation, Appointment and Acceptance dated December 27, 2007 among the Company, the Guarantor, Law Debenture Trust Company of New York and Citibank, N.A.), as t
UNDERWRITING AGREEMENT among GLAXOSMITHKLINE CAPITAL PLC as Issuer GLAXOSMITHKLINE PLC as Guarantor and as Representatives of the Underwriters Dated as of [ ]Underwriting Agreement • March 4th, 2008 • Glaxosmithkline Capital PLC • Pharmaceutical preparations • New York
Contract Type FiledMarch 4th, 2008 Company Industry JurisdictionWe have acted as special United States counsel to GlaxoSmithKline Capital plc, a public limited company incorporated in England and Wales (“GSK Capital”), and GlaxoSmithKline plc, a public limited company incorporated in England and Wales (the “Guarantor”), in connection with the offering from time to time, together or separately and in one or more series, pursuant to a registration statement on Form F-3 (No. 333-[ ]) of (i) guaranteed debt securities of GSK Capital (the “Debt Securities”) and (ii) guarantees of the Guarantor in respect of the Debt Securities (the “Guarantees” and, together with the Debt Securities, the “Securities”) to be issued under an indenture dated as of April 6, 2004 (the “Indenture”) among GSK Capital, the Guarantor and Law Debenture Trust Company of New York (as successor to Citibank, N.A., pursuant to an Instrument of Resignation, Appointment and Acceptance dated December 27, 2007 among the Company, the Guarantor, Law Debenture Trust Company of New York and C